Asia Pacific Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity

September 2020 | 122 pages | ID: AA26F8AACD71EN
GMD Research

Abstracts

Asia Pacific pharmacogenomics market will grow by 10.3% annually with a total addressable market cap of $21.7 billion over 2020-2030 owing to the rising adoption of personalized medicine and usage of pharmacogenomics for drug discovery and development amid COVID-19 pandemic.

Highlighted with 35 tables and 49 figures, this 122-page report “Asia Pacific Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific pharmacogenomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmacogenomics market in every aspect of the classification from perspectives of Service, Technology, Application, End User, and Country.

Based on Service, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Genotyping
• SNP Identification
• Diagnostics
• Other Services

Based on Technology, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Polymerase Chain Reaction (PCR)
• Microarray
• Sequencing
• Electrophoresis
• Mass Spectrometry
• Other Technologies

Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Oncology
• Infectious Diseases
• Neurology/Psychiatry
• Cardiovascular
• Pain Management
• Other Applications

Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Hospitals and Clinics
• Pharmaceutical Companies
• Research Institutes

Geographically, the following national/local markets are fully investigated:

• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

Detailed analysis and annual revenue 2019-2030 are available for each key national market. The breakdown of key national markets by Service, Technology, and Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Asia Pacific pharmacogenomics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):

23andMe, Inc.
Abbott Laboratories
Admera Health, LLC
Agena Biosciences, Inc.
Astra Zeneca PLC
Bayer AG
Becton, Dickinson and Company
Cancer Genetics, Inc.
Dynamic DNA Laboratories
Empire Genomics LLC
F. Hoffmann-La Roche Ltd
geneOmbio Technologies Pvt Ltd.
Genomic Health, Inc.
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics Inc.
Oneome LLC
Opko Health, Inc.
Pathway Genomics Corporation
QIAGEN N.V.
Quest Diagnostics Incorporated
Teva Pharmaceuticals Industries Ltd.
Thermo Fisher Scientific Inc.
Transgenomic, Inc.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Market Research Methodology
  1.2.2 Market Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Market Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

2.1 Market Size and Forecast
  2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF ASIA PACIFIC MARKET BY SERVICE

3.1 Market Overview by Service
3.2 Genotyping
3.3 SNP Identification
3.4 Diagnostics
3.5 Other Services

4 SEGMENTATION OF ASIA PACIFIC MARKET BY TECHNOLOGY

4.1 Market Overview by Technology
4.2 Polymerase Chain Reaction (PCR)
4.3 Microarray
4.4 Sequencing
4.5 Electrophoresis
4.6 Mass Spectrometry
4.7 Other Technologies

5 SEGMENTATION OF ASIA PACIFIC MARKET BY APPLICATION

5.1 Market Overview by Application
5.2 Oncology
5.3 Infectious Diseases
5.4 Neurology/Psychiatry
5.5 Cardiovascular
5.6 Pain Management
5.7 Other Applications

6 SEGMENTATION OF ASIA PACIFIC MARKET BY END USER

6.1 Market Overview by End User
6.2 Hospitals and Clinics
6.3 Pharmaceutical Companies
6.4 Research Institutes

7 ASIA-PACIFIC MARKET 2019-2030 BY COUNTRY

7.1 Overview of Asia-Pacific Market
7.2 Japan
7.3 China
7.4 Australia
7.5 India
7.6 South Korea
7.7 Rest of APAC Region

8 COMPETITIVE LANDSCAPE

8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles

23ANDME, INC.

Abbott Laboratories
Admera Health, LLC
Agena Biosciences, Inc.
Astra Zeneca PLC
Bayer AG
Becton, Dickinson and Company
Cancer Genetics, Inc.
Dynamic DNA Laboratories
Empire Genomics LLC
F. Hoffmann-La Roche Ltd
geneOmbio Technologies Pvt Ltd.
Genomic Health, Inc.
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics Inc.
Oneome LLC
Opko Health, Inc.
Pathway Genomics Corporation
QIAGEN N.V.
Quest Diagnostics Incorporated
Teva Pharmaceuticals Industries Ltd.
Thermo Fisher Scientific Inc.
Transgenomic, Inc.

9 INVESTING IN ASIA PACIFIC MARKET: RISK ASSESSMENT AND MANAGEMENT

9.1 Risk Evaluation of Asia Pacific Market
9.2 Critical Success Factors (CSFs)
Related Reports and Products

List Of Tables

LIST OF TABLES

Table 1. Snapshot of Asia Pacific Pharmacogenomics Market, 2019-2030
Table 2. Web-based Resources of Pharmacogenomics
Table 3. Main Product Trends and Market Opportunities in Asia Pacific Pharmacogenomics Market
Table 4. Asia Pacific Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 5. Medicine/Gene Matching in Pharmacogenetic Testing
Table 6. Asia Pacific Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 7. Asia Pacific Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 8. Important Drug-Gene Pairs Relevant to Neurology and Psychiatry
Table 9. Asia Pacific Pharmacogenomics Market by End User, 2019-2030, $ mn
Table 10. APAC Pharmacogenomics Market by Country, 2019-2030, $ mn
Table 11. Japan Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 12. Japan Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 13. Japan Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 14. China Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 15. China Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 16. China Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 17. Australia Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 18. Australia Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 19. Australia Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 20. India Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 21. India Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 22. India Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 23. South Korea Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 24. South Korea Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 25. South Korea Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 26. Pharmacogenomics Market in Rest of APAC by Country, 2019-2030, $ mn
Table 27. Product Approvals by Company, January 2016 – April 2019
Table 28. Breakdown of Asia Pacific Market by Key Vendor, 2019, %
Table 29. 23andMe, Inc.: Company Snapshot
Table 30. 23andMe, Inc.: Business Segmentation
Table 31. 23andMe, Inc.: Product Portfolio
Table 32. 23andMe, Inc.: Revenue, 2016-2018, $ mn
Table 33. 23andMe, Inc.: Recent Developments
Table 34. Risk Evaluation for Investing in Asia Pacific Market, 2019-2030
Table 35. Critical Success Factors and Key Takeaways

List Of Figures

LIST OF FIGURES

Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. Asia Pacific Pharmacogenomics Market, 2019-2030, $ mn
Figure 6. An Overall Process of How Pharmacogenomics Functions in a Clinical Practice
Figure 7. Impact of COVID-19 on Business
Figure 8. Primary Drivers and Impact Factors of Asia Pacific Pharmacogenomics Market
Figure 9. World Top 10 Causes of Deaths, 2016
Figure 10. Primary Restraints and Impact Factors of Asia Pacific Pharmacogenomics Market
Figure 11. Consecutive Phases and Associated Challenges in Pharmacogenomics
Figure 12. Investment Opportunity Analysis
Figure 13. Porter’s Fiver Forces Analysis of Asia Pacific Pharmacogenomics Market
Figure 14. Breakdown of Asia Pacific Pharmacogenomics Market by Service, 2019-2030, % of Revenue
Figure 15. Asia Pacific Addressable Market Cap in 2020-2030 by Service, Value ($ mn) and Share (%)
Figure 16. Asia Pacific Pharmacogenomics Market: Genotyping, 2019-2030, $ mn
Figure 17. Asia Pacific Pharmacogenomics Market: SNP Identification, 2019-2030, $ mn
Figure 18. Asia Pacific Pharmacogenomics Market: Diagnostics, 2019-2030, $ mn
Figure 19. Asia Pacific Pharmacogenomics Market: Other Services, 2019-2030, $ mn
Figure 20. Breakdown of Asia Pacific Pharmacogenomics Market by Technology, 2019-2030, % of Sales Revenue
Figure 21. Asia Pacific Addressable Market Cap in 2020-2030 by Technology, Value ($ mn) and Share (%)
Figure 22. Asia Pacific Pharmacogenomics Market: Polymerase Chain Reaction (PCR), 2019-2030, $ mn
Figure 23. Asia Pacific Pharmacogenomics Market: Microarray, 2019-2030, $ mn
Figure 24. Asia Pacific Pharmacogenomics Market: Sequencing, 2019-2030, $ mn
Figure 25. Asia Pacific Pharmacogenomics Market: Electrophoresis, 2019-2030, $ mn
Figure 26. Asia Pacific Pharmacogenomics Market: Mass Spectrometry, 2019-2030, $ mn
Figure 27. Asia Pacific Pharmacogenomics Market: Other Technologies, 2019-2030, $ mn
Figure 28. Breakdown of Asia Pacific Pharmacogenomics Market by Application, 2019-2030, % of Sales Revenue
Figure 29. Asia Pacific Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%)
Figure 30. Asia Pacific Pharmacogenomics Market: Oncology, 2019-2030, $ mn
Figure 31. Asia Pacific Pharmacogenomics Market: Infectious Diseases, 2019-2030, $ mn
Figure 32. Asia Pacific Pharmacogenomics Market: Neurology/Psychiatry, 2019-2030, $ mn
Figure 33. Asia Pacific Pharmacogenomics Market: Cardiovascular, 2019-2030, $ mn
Figure 34. Asia Pacific Pharmacogenomics Market: Pain Management, 2019-2030, $ mn
Figure 35. Asia Pacific Pharmacogenomics Market: Other Applications, 2019-2030, $ mn
Figure 36. Breakdown of Asia Pacific Pharmacogenomics Market by End User, 2019-2030, % of Revenue
Figure 37. Asia Pacific Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%)
Figure 38. Asia Pacific Pharmacogenomics Market: Hospitals and Clinics, 2019-2030, $ mn
Figure 39. Asia Pacific Pharmacogenomics Market: Pharmaceutical Companies, 2019-2030, $ mn
Figure 40. Asia Pacific Pharmacogenomics Market: Research Institutes, 2019-2030, $ mn
Figure 41. Breakdown of APAC Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue
Figure 42. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 43. Pharmacogenomics Market in Japan, 2019-2030, $ mn
Figure 44. Pharmacogenomics Market in China, 2019-2030, $ mn
Figure 45. Pharmacogenomics Market in Australia, 2019-2030, $ mn
Figure 46. Pharmacogenomics Market in India, 2019-2030, $ mn
Figure 47. Pharmacogenomics Market in South Korea, 2019-2030, $ mn
Figure 48. Pharmacogenomics Market in Rest of APAC, 2019-2030, $ mn
Figure 49. Growth Stage of Asia Pacific Pharmacogenomics Industry over the Forecast Period


COMPANIES MENTIONED

3M Health Care Limited
Adherium Limited
Amiko Digital Health Limited
AsthmaMD
AstraZeneca plc
Boehringer Ingelheim International GmbH
Capsule Technologies, Inc.
Cohero Health
GlaxoSmithKline plc
Kaia Health Software GmbH
Medical International Research (MIR)
Novartis AG
NuvoAir
Reciprocal Labs (Propeller Health)
Sensiron AG
Tactio Health
Teva Pharmaceuticals Industries Ltd.